BMB Reports

Korean Society for Biochemistry and Molecular Biology (생화학분자생물학회)
권호 표지
DOI QR코드

DOI QR Code

C-terminal truncated HBx reduces doxorubicin cytotoxicity via ABCB1 upregulation in Huh-7 hepatocellular carcinoma cells

  • Jegal, Myeong-Eun (Department of Molecular Biology, College of Natural Science, Pusan National University) ;
  • Jung, Seung-Youn (Department of Molecular Biology, College of Natural Science, Pusan National University) ;
  • Han, Yu-Seon (Department of Molecular Biology, College of Natural Science, Pusan National University) ;
  • Kim, Yung-Jin (Department of Molecular Biology, College of Natural Science, Pusan National University)
  • Received : 2018.12.20
  • Accepted : 2019.03.12
  • Published : 2019.05.31
Download PDF
⟨ Previous Next ⟩

Abstract

Hepatitis B virus (HBV) encoding the HBV x protein (HBx) is a known causative agent of hepatocellular carcinoma (HCC). Its pathogenic activities in HCC include interference with several signaling pathways associated with cell proliferation and apoptosis. Mutant C-terminal-truncated HBx isoforms are frequently found in human HCC and have been shown to enhance proliferation and invasiveness leading to HCC malignancy. We investigated the molecular mechanism of the reduced doxorubicin cytotoxicity by C-terminal truncated HBx. Cells transfected with C-terminal truncated HBx exhibited reduced cytotoxicity to doxorubicin compared to those transfected with full-length HBx. The doxorubicin resistance of cells expressing C-terminal truncated HBx correlated with upregulation of the ATP binding cassette subfamily B member 1(ABCB1) transporter, resulting in the enhanced efflux of doxorubicin. Inhibiting the activity of ABCB1 and silencing ABCB1 expression by small interfering ribonucleic acid (siRNA) increased the cytotoxicity of doxorubicin. These results indicate that elevated ABCB1 expression induced by C-terminal truncation of HBx was responsible for doxorubicin resistance in HCC. Hence, co-treatment with an ABCB1 inhibitor and an anticancer agent may be effective for the treatment of patients with liver cancer containing the C-terminal truncated HBx.

Keywords

References

  1. Liu N, Chen T, Wang X, Yang D, Xue B and Zhu H (2015) Msi1 confers resistance to TRAIL by activating ERK in liver cancer cells. FEBS Lett 589, 897-903 https://doi.org/10.1016/j.febslet.2015.02.026
  2. Arzumanyan A, Reis HM and Feitelson MA (2013) Pathogenic mechanisms in HBV- and HCV-associated hepatocellular carcinoma. Nat Rev Cancer 13, 123-135 https://doi.org/10.1038/nrc3449
  3. Martin-Vilchez S, Lara-Pezzi E, Trapero-Marugan M, Moreno-Otero R and Sanz-Cameno P (2011) The molecular and pathophysiological implications of hepatitis B X antigen in chronic hepatitis B virus infection. Rev Med Virol 21, 315-329 https://doi.org/10.1002/rmv.699
  4. Ng SA and Lee C (2011) Hepatitis B virus X gene and hepatocarcinogenesis. J Gastroenterol 46, 974-990 https://doi.org/10.1007/s00535-011-0415-9
  5. Kim CM, Koike K, Saito I, Miyamura T and Jay G (1991) HBx gene of hepatitis B virus induces liver cancer in transgenic mice. Nature 351, 317-320 https://doi.org/10.1038/351317a0
  6. Fan W, Shi B, Wei H, Du G and Song S (2011) Comparison of hepatitis B X gene mutation between patients with hepatocellular carcinoma and patients with chronic hepatitis B. Virus Genes 42, 162-170 https://doi.org/10.1007/s11262-010-0557-5
  7. Ali A, Abdel-Hafiz H, Suhail M et al (2014) Hepatitis B virus, HBx mutants and their role in hepatocellular carcinoma. World J Gastroenterol 20, 10238-10248 https://doi.org/10.3748/wjg.v20.i30.10238
  8. Wang J, Alexanian A, Ying R et al (2012) Acute exposure to low glucose rapidly induces endothelial dysfunction and mitochondrial oxidative stress: role for AMP kinase. Arterioscler Thromb Vasc Biol 32, 712-720 https://doi.org/10.1161/ATVBAHA.111.227389
  9. Sze KM, Chu GK, Lee JM and Ng IO (2013) C-terminal truncated hepatitis B virus x protein is associated with metastasis and enhances invasiveness by C-Jun/matrix metalloproteinase protein 10 activation in hepatocellular carcinoma. Hepatology 57, 131-139 https://doi.org/10.1002/hep.25979
  10. Zhang H, Shan CL, Li N et al (2008) Identification of a natural mutant of HBV X protein truncated 27 amino acids at the COOH terminal and its effect on liver cell proliferation. Acta Pharmacol Sin 29, 473-480 https://doi.org/10.1111/j.1745-7254.2008.00764.x
  11. Zhang X, Ye LH and Zhang XD (2010) A mutant of hepatitis B virus X protein (HBx Delta 127) enhances hepatoma cell migration via osteopontin involving 5-lipoxygenase. Acta Pharmacol Sin 31, 593-600 https://doi.org/10.1038/aps.2010.36
  12. Ma NF, Lau SH, Hu L et al (2008) COOH-terminal truncated HBV X protein plays key role in hepatocarcinogenesis. Clin Cancer Res 14, 5061-5068 https://doi.org/10.1158/1078-0432.CCR-07-5082
  13. Quetier I, Brezillon N, Revaud J et al (2015) C-terminaltruncated hepatitis B virus X protein enhances the development of diethylnitrosamine-induced hepatocellular carcinogenesis. J Gen Virol 96, 614-625 https://doi.org/10.1099/vir.0.070680-0
  14. Ng KY, Chai S, Tong M et al (2016) C-terminal truncated hepatitis B virus X protein promotes hepatocellular carcinogenesis through induction of cancer and stem cell-like properties. Oncotarget 7, 24005-24017 https://doi.org/10.18632/oncotarget.8209
  15. Kachalaki S, Ebrahimi M, Mohamed Khosroshahi L, Mohammadinejad S and Baradaran B (2016) Cancer chemoresistance; biochemical and molecular aspects: a brief overview. Eur J Pharm Sci 89, 20-30 https://doi.org/10.1016/j.ejps.2016.03.025
  16. Wu Q, Yang Z, Nie Y, Shi Y and Fan D (2014) Multi-drug resistance in cancer chemotherapeutics: mechanisms and lab approaches. Cancer Lett 347, 159-166 https://doi.org/10.1016/j.canlet.2014.03.013
  17. Kathawala RJ, Gupta P, Ashby CR Jr and Chen ZS (2015) The modulation of ABC transporter-mediated multidrug resistance in cancer: a review of the past decade. Drug Resist Updat 18, 1-17 https://doi.org/10.1016/j.drup.2014.11.002
  18. Januchowski R, Wojtowicz K, Andrzejewska M and Zabel M (2014) Expression of MDR1 and MDR3 gene products in paclitaxel-, doxorubicin- and vincristine-resistant cell lines. Biomed Pharmacother 68, 111-117 https://doi.org/10.1016/j.biopha.2013.09.004
  19. Dean M, Fojo T and Bates S (2005) Tumour stem cells and drug resistance. Nat Rev Cancer 5, 275-284 https://doi.org/10.1038/nrc1590
  20. Saad M, Garbuzenko OB and Minko T (2008) Co-delivery of siRNA and an anticancer drug for treatment of multidrug-resistant cancer. Nanomedicine (Lond) 3, 761-776 https://doi.org/10.2217/17435889.3.6.761
  21. Nourbakhsh M, Jaafari MR, Lage H et al (2015) Nanolipoparticles-mediated MDR1 siRNA delivery reduces doxorubicin resistance in breast cancer cells and silences MDR1 expression in xenograft model of human breast cancer. Iran J Basic Med Sci 18, 385-392
  22. Jung SY and Kim YJ (2013) C-terminal region of HBx is crucial for mitochondrial DNA damage. Cancer Lett 331, 76-83 https://doi.org/10.1016/j.canlet.2012.12.004
  23. Broxterman HJ, Gotink KJ and Verheul HM (2009) Understanding the causes of multidrug resistance in cancer: a comparison of doxorubicin and sunitinib. Drug Resist Updat 12, 114-126 https://doi.org/10.1016/j.drup.2009.07.001
  24. Llovet JM (2005) Updated treatment approach to hepatocellular carcinoma. J Gastroenterol 40, 225-235 https://doi.org/10.1007/s00535-005-1566-3
  25. Yeo W, Lam KC, Zee B et al (2004) Hepatitis B reactivation in patients with hepatocellular carcinoma undergoing systemic chemotherapy. Ann Oncol 15, 1661-1666 https://doi.org/10.1093/annonc/mdh430
  26. Gewirtz DA (1999) A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem Pharmacol 57, 727-741 https://doi.org/10.1016/S0006-2952(98)00307-4
  27. Nitiss KC and Nitiss JL (2014) Twisting and ironing: doxorubicin cardiotoxicity by mitochondrial DNA damage. Clin Cancer Res 20, 4737-4739 https://doi.org/10.1158/1078-0432.CCR-14-0821